Hansoh Pharma Receives Breakthrough Therapy Designation for HS-20093 in Treating Extensive-Stage Small Cell Lung Cancer
Hansoh Pharmaceutical has announced that its self-developed B7-H3-targeted antibody-drug conjugate (ADC), HS-20093, has been designated as a Breakthrough Therapy by China’s National Medical Products Administration (NMPA).
This designation is for treating extensive-stage small cell lung cancer (ES-SCLC) in patients whose disease has progressed after first-line treatment with platinum-based chemotherapy and immunotherapy.
HS-20093 is an innovative B7-H3-targeted ADC, combining a fully humanised anti-B7-H3 monoclonal antibody with a topoisomerase inhibitor (TOPOi) payload.
It is in Phase III clinical trials in China for small cell lung cancer and in early-phase trials (Phase I and II) for other cancers, including sarcoma, head and neck cancers, oesophageal squamous cell carcinoma (ESCC), and other solid tumours.
Lung cancer is one of the most common cancers globally. Around 70% of small cell lung cancer cases are diagnosed at an extensive stage, meaning the cancer has spread beyond the lungs to other areas of the body.
ES-SCLC is particularly aggressive, with limited treatment options. The five-year survival rate is approximately 3%. Most patients relapse after initial treatment, and the current standard therapies for relapsed ES-SCLC offer a median survival of just 5–6 months.
